CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-28 | Espinoza Octavio Chief Financial Officer | Other acquisition | +267 | $60.71 | $16K | 23,646 |
| 2024-06-28 | Davis Todd C Chief Executive Officer | Other acquisition | +350 | $60.71 | $21K | 120,510 |
| 2024-06-14 | Sabba Stephen L Director | Grant or award | +1,252 | 30,178 | ||
| 2024-06-14 | Sabba Stephen L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | Zimmermann Martine Director | Grant or award | +1,252 | 3,537 | ||
| 2024-06-14 | Zimmermann Martine Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | LAMATTINA JOHN L Director | Grant or award | +1,252 | 29,515 | ||
| 2024-06-14 | LAMATTINA JOHN L Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | KOZARICH JOHN W Director | Grant or award | +1,252 | 43,775 | ||
| 2024-06-14 | KOZARICH JOHN W Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | Haas Jason Director | Grant or award | +1,252 | 5,397 | ||
| 2024-06-14 | Haas Jason Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | Gray Nancy Ryan Director | Grant or award | +1,252 | 6,885 | ||
| 2024-06-14 | Gray Nancy Ryan Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-06-14 | Aryeh Jason Director | Grant or award | +1,252 | 78,080 | ||
| 2024-06-14 | Aryeh Jason Director | Grant or award · Non-Qualified Stock Option (right to buy) | +5,444 | 5,444 | ||
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise | +206 | $57.22 | $12K | 21,824 |
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise | +1,544 | $63.62 | $98K | 23,368 |
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise | +145 | $68.74 | $10K | 23,513 |
| 2024-05-17 | Espinoza Octavio Chief Financial Officer | Option exercise | +5,022 | $52.84 | $265K | 28,535 |
Page 21 of 43 · 858 trades